JOHN KIRKWOOD to Dendritic Cells
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Dendritic Cells.
Connection Strength
1.461
-
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021 11; 9(11).
Score: 0.520
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
Score: 0.436
-
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
Score: 0.121
-
Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018 06; 28(3):211-221.
Score: 0.103
-
Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012 Sep-Oct; 62(5):309-35.
Score: 0.067
-
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011 Apr; 34(3):270-8.
Score: 0.062
-
Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother. 2007 Jan; 30(1):75-82.
Score: 0.046
-
NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 01; 62(1):213-8.
Score: 0.033
-
Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
Score: 0.030
-
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017 Sep 01; 23(17):5034-5043.
Score: 0.024
-
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 01; 174(3):1751-9.
Score: 0.010
-
The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 2003 Oct 01; 63(19):6506-15.
Score: 0.009